-
Armodafinil as a Potential Pharmacological Treatment for Attention Deficit Hyperactivity Disorder in Adults: A Review Curr. Neuropharmacol. (IF 5.3) Pub Date : 2024-03-16 Reyna Lamas-Aguilar, Araceli Diaz-Ruiz, Luz Navarro, Raúl Miranda-Ojeda, María de los Ángeles Martínez-Cárdenas, Alfonso Mata-Bermudez, Camilo Rios
Introduction: Armodafinil is a psychostimulant that promotes alertness, and it has been shown to improve attention, memory, and fatigue in healthy adults and adults with neurodevelopmental conditions that share symptoms with Attention Deficit Hyperactivity Disorder (ADHD). It is generally well tolerated and safe, and most of the adverse events reported are considered not serious. However, the available
-
A Mechanistic Review on Protective Effects of Mangosteen and its Xanthones Against Hazardous Materials and Toxins Curr. Neuropharmacol. (IF 5.3) Pub Date : 2024-03-16 Roghayeh Yahyazadeh, Vafa Baradaran Rahimi, Ahmad Yahyazadeh, Vahid Reza Askari
: Due to its pharmacological properties, α-Mangostin, mainly found in Garcinia mangostana (G.mangostana) L. (Mangosteen, queen of fruits), treats wounds, skin infections, and many other disorders. In fact, α-Mangostin and other xanthonoid, including β-Mangostin and γ-Mangostin, are found in G. mangostana, which have various advantages, namely neuroprotective, anti-proliferative, antinociceptive, antioxidant
-
Gut Microbiome in Alzheimer’s Disease: from Mice to Humans Curr. Neuropharmacol. (IF 5.3) Pub Date : 2024-03-16 Chang Liang, Resel Pereira, Yan Zhang, Olga L. Rojas
: Alzheimer's disease (AD) is the most prevalent type of dementia, but its etiopathogenesis is not yet fully understood. Recent preclinical studies and clinical evidence indicate that changes in the gut microbiome could potentially play a role in the accumulation of amyloid beta. However, the relationship between gut dysbiosis and AD is still elusive. In this review, the potential impact of the gut
-
Two Distinct Neuronal Populations in the Rat Parafascicular Nucleus Oppositely Encode the Engagement in Stimulus-driven Reward-seeking Curr. Neuropharmacol. (IF 5.3) Pub Date : 2024-02-29 Mehdi Sicre, Frederic Ambroggi, Julie Meffre
Background:: The thalamus is a phylogenetically well-preserved structure. Known to densely contact cortical regions, its role in the transmission of sensory information to the striatal complex has been widely reconsidered in recent years. Methods:: The parafascicular nucleus of the thalamus (Pf) has been implicated in the orientation of attention toward salient sensory stimuli. In a stimulus-driven
-
The Integration of Top-down and Bottom-up Inputs to the Striatal Cholinergic Interneurons Curr. Neuropharmacol. (IF 5.3) Pub Date : 2024-02-29 Yan-Feng Zhang, John N.J. Reynolds
Background: Cholinergic interneurons (ChIs) are important for learning and memory. They exhibit a multiphasic excitation-pause-rebound response to reward or sensory cues indicating a reward, believed to gate dopamine-dependent learning. Although ChIs receive extensive top-down inputs from the cortex and bottom-up inputs from the thalamus and midbrain, it is unclear which inputs are involved in the
-
CREB: A Promising Therapeutic Target for Treating Psychiatric Disorders Curr. Neuropharmacol. (IF 5.3) Pub Date : 2024-02-19 Wei Guan, Mei-Xin Ni, Hai-Juan Gu, Yang Yang
: Psychiatric disorders are complex, multifactorial illnesses. It is challenging for us to understand the underlying mechanism of psychiatric disorders. In recent years, the morbidity of psychiatric disorders has increased yearly, causing huge economic losses to the society. Although some progress, such as psychotherapy drugs and electroconvulsive therapy, has been made in the treatment of psychiatric
-
Protective Role of Electroacupuncture Against Cognitive Impairment in Neurological Diseases Curr. Neuropharmacol. (IF 5.3) Pub Date : 2024-02-16 Yueyang Xin, Siqi Zhou, Tiantian Chu, Yaqun Zhou, Aijun Xu
: Many neurological diseases can lead to cognitive impairment in patients, which includes dementia and mild cognitive impairment and thus create a heavy burden both to their families and public health. Due to the limited effectiveness of medications in treating cognitive impairment, it is imperative to develop alternative treatments. Electroacupuncture (EA), a required method for Traditional Chinese
-
Effects of Prenatal Methcathinone Exposure on the Neurological Behavior of Adult Offspring Curr. Neuropharmacol. (IF 5.3) Pub Date : 2024-02-09 Zhang Youyou, Li Zhaoyang, Li Chen, Zhao Shuquan, Wang Hui
Background:: Our previous research has shown that prenatal methcathinone exposure affects the neurodevelopment and neurobehavior of adolescent offspring, but the study on whether these findings continue into adulthood is limited. Objective:: This study aims to explore the effects of prenatal methcathinone exposure on anxiety-like behavior, learning and memory abilities, as well as serum 5-hydroxytryptamine
-
Local and Remote Chemogenetic Suppression of Hippocampal Seizures in Rats Curr. Neuropharmacol. (IF 5.3) Pub Date : 2024-02-09 Donghong Li, Xi Yan, Yue Xing, Jiaqing Yan, Junling Wang, Herui Zhang, Jiaoyang Wang, Xiaonan Li, Zhumin Su, Horace Hao Loh, Xiaofeng Yang, Xiaohong Chen
Background:: Innovative treatments of refractory epilepsy are widely desired, for which chemogenetic technology can provide region- and cell-type-specific modulation with relative noninvasiveness. Objectives:: We aimed to explore the specific applications of chemogenetics for locally and remotely networks controlling hippocampal seizures Methods:: A virus coding for a modified human Gi-coupled M4 muscarinic
-
Metabolic Reprogramming in Gliocyte Post-cerebral Ischemia/ Reperfusion: From Pathophysiology to Therapeutic Potential Curr. Neuropharmacol. (IF 5.3) Pub Date : 2024-02-09 Lipeng Gong, Junjie Liang, Letian Xie, Zhanwei Zhang, Zhigang Mei, Wenli Zhang
Ischemic stroke is a leading cause of disability and death worldwide. However, the clinical efficacy of recanalization therapy as a preferred option is significantly hindered by reperfusion injury. The transformation between different phenotypes of gliocytes is closely associated with cerebral ischemia/ reperfusion injury (CI/RI). Moreover, gliocyte polarization induces metabolic reprogramming, which
-
Modulating Mitochondrial Dynamics Mitigates Cognitive Impairment in Rats with Myocardial Infarction Curr. Neuropharmacol. (IF 5.3) Pub Date : 2024-01-31 Kewarin Jinawong, Chanon Piamsiri, Nattayaporn Apaijai, Chayodom Maneechote, Busarin Arunsak, Wichwara Nawara, Chanisa Thonusin, Hiranya Pintana, Nipon Chattipakorn, Siriporn C. Chattipakorn
Background: We have previously demonstrated that oxidative stress and brain mitochondrial dysfunction are key mediators of brain pathology during myocardial infarction (MI). Objective: To investigate the beneficial effects of mitochondrial dynamic modulators, including mitochondrial fission inhibitor (Mdivi-1) and mitochondrial fusion promotor (M1), on cognitive function and molecular signaling in
-
Emerging Neuroprotective Strategies: Unraveling the Potential of HDAC Inhibitors in Traumatic Brain Injury Management Curr. Neuropharmacol. (IF 5.3) Pub Date : 2024-01-29 Lisha Ye, Wenfeng Li, Xiaoyan Tang, Ting Xu, Guohua Wang
: Traumatic brain injury (TBI) is a significant global health problem, leading to high rates of mortality and disability. It occurs when an external force damages the brain, causing immediate harm and triggering further pathological processes that exacerbate the condition. Despite its widespread impact, the underlying mechanisms of TBI remain poorly understood, and there are no specific pharmacological
-
Astrocytes and Memory: Implications for the Treatment of Memory-related Disorders Curr. Neuropharmacol. (IF 5.3) Pub Date : 2024-01-29 Juan Wang, Ping Cheng, Yan Qu, Guoqi Zhu
:: Memory refers to the imprint accumulated in the brain by life experiences and represents the basis for humans to engage in advanced psychological activities such as thinking and imagination. Previously, research activities focused on memory have always targeted neurons. However, in addition to neurons, astrocytes are also involved in the encoding, consolidation, and extinction of memory. In particular
-
Targeting Histamine and Histamine Receptors for Memory Regulation: An Emotional Perspective Curr. Neuropharmacol. (IF 5.3) Pub Date : 2024-01-29 Zhuowen Fang, Jiahui Chen, Yanrong Zheng, Zhong Chen
: Histamine has long been accepted as a pro-cognitive agent. However, lines of evidence have suggested that the roles of histamine in learning and memory processes are much more complex than previously thought. When explained by the spatial perspectives, there are many contradictory results. However, using emotional memory perspectives, we suspect that the histaminergic system may interplay with stress
-
Cariprazine Augmentation in Treatment-Resistant Bipolar Depression: Data from a Retrospective Observational Study Curr. Neuropharmacol. (IF 5.3) Pub Date : 2024-01-29 Elena Teobaldi, Enrico Pessina, Azzurra Martini, Carlo Ignazio Cattaneo, Domenico De Berardis, Vassilis Martiadis, Giuseppe Maina, Gianluca Rosso
Background: Treatment-resistant bipolar depression is one of the leading problems in psychiatry with serious consequences on patients functioning, quality of life and resource utilization. Despite this, there is a lack of consensus on diagnostic criteria and treatment algorithms. Objective: The objective of the present study is to assess the acute effectiveness and tolerability of cariprazine in the
-
Affective and Cognitive Impairments in Rodent Models of Diabetes Curr. Neuropharmacol. (IF 5.3) Pub Date : 2024-01-26 Enza Palazzo, Ida Marabese, Serena Boccella, Carmela Belardo, Gorizio Pierretti, Sabatino Maione
: Diabetes and related acute and long-term complications have a profound impact on cognitive, emotional, and social behavior, suggesting that the central nervous system (CNS) is a crucial substrate for diabetic complications. When anxiety, depression, and cognitive deficits occur in diabetic patients, the symptoms and complications related to the disease worsen, contributing to lower quality of life
-
Disease Modifying Strategies in Multiple Sclerosis: New Rays of Hope to Combat Disability? Curr. Neuropharmacol. (IF 5.3) Pub Date : 2024-01-25 Carlo Maria Maria Bellanca, Egle Augello, Alice Mariottini, Gabriele Bonaventura, Valentina La Cognata, Giulia Di Benedetto, Anna Flavia Cantone, Giuseppe Attaguile, Rosaria Di Mauro, Giuseppina Cantarella, Luca Massacesi, Renato Bernardini
: Multiple sclerosis (MS) is the most prevalent chronic autoimmune inflammatory- demyelinating disorder of the central nervous system (CNS). It usually begins in young adulthood, mainly between the second and fourth decades of life. Usually, the clinical course is characterized by the involvement of multiple CNS functional systems and by different, often overlapping phenotypes. In the last decades
-
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment Curr. Neuropharmacol. (IF 5.3) Pub Date : 2024-01-05 Tamar Glatman Zaretsky, Kathleen M. Jagodnik, Robert Barsic, Josimar Hernandez Antonio, Philip A. Bonanno, Carolyn MacLeod, Charlotte Pierce, Hunter Carney, Morgan T. Morrison, Charles Saylor, George Danias, Lauren Lepow, Rachel Yehuda
: Post-traumatic stress disorder (PTSD) is a mental health condition that can occur following exposure to a traumatic experience. An estimated 12 million U.S. adults are presently affected by this disorder. Current treatments include psychological therapies (e.g., exposure-based interventions) and pharmacological treatments (e.g., selective serotonin reuptake inhibitors (SSRIs)). However, a significant
-
Redox Modulation of Meniere Disease by Coriolus Versicolor Treatment, a Nutritional Mushroom Approach with Neuroprotective Potential Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-12-11 Rosanna Di Paola, Rosalba Siracusa, Roberta Fusco, Marialaura Ontario, Gaetano Cammilleri, Licia Pantano, Maria Scuto, Mario Tomasello, Sestina Spanò, Angela Trovato Salinaro, Ali S. Abdelhameed, Vincenzo Ferrantelli, Antonio Arcidiacono, Tilman Fritsch, Gabriella Lupo, Anna Signorile, Luigi Maiolino, Salvatore Cuzzocrea, Vittorio Calabrese
Background: Meniere’s disease (MD) is a cochlear neurodegenerative disease. Hearing loss appears to be triggered by oxidative stress in the ganglion neurons of the inner ear. Objective: Here, we confirm the variation of markers of oxidative stress and inflammation in patients with Meniere and hypothesize that chronic treatment with Coriolus mushroom helps in the response to oxidative stress and acts
-
In Vitro Blood-Brain Barrier Models for Neuroinfectious Diseases: A Narrative Review Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-12-08 Ahmad Hussein Badawi, Nur Afiqah Mohamad, Johnson Stanslas, Brian Patrick Kirby, Vasantha Kumari Neela, Rajesh Ramasamy, Hamidon Basri
The blood-brain barrier (BBB) is a complex, dynamic, and adaptable barrier between the peripheral blood system and the central nervous system. While this barrier protects the brain and spinal cord from inflammation and infection, it prevents most drugs from reaching the brain tissue. With the expanding interest in the pathophysiology of BBB, the development of in vitro BBB models has dramatically evolved
-
Biphasic Hormetic-like Effect of Lebecetin, a C-type Lectin of Snake Venom, on Formalin-induced Inflammation in Mice Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-12-08 Carmela Belardo, Jed Jebali, Serena Boccella, Rosmara Infantino, Antimo Fusco, Michela Perrone, Roozbe Bonsale, Iolanda Manzo, Monica Iannotta, Damiana Scuteri, Franca Ferraraccio, Iacopo Panarese, Giovanna Ferrara, Francesca Guida, Livio Luongo, Enza Palazzo, Najet Srairi-Abid, Naziha Marrakchi, Sabatino Maione
Background: Integrins, important extracellular matrix (ECM) receptor proteins, are affected by inflammation and can participate in the maintenance of many painful conditions. Although they are ubiquitous and changeable across all cell types, the roles of these cell adhesion molecules in pathological pain have not been fully explored. Objective: We evaluated the effects of the subcutaneous injection
-
Immunomodulatory Effects of Clozapine: More Than Just a Side Effect in Schizophrenia Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-11-28 Andrea Amerio, Luca Magnani, Gabriele Arduino, Fabio Fesce, Renato de Filippis, Alberto Parise, Alessandra Costanza, Khoa D. Nguyen, Daniele Saverino, Domenico De Berardis, Andrea Aguglia, Andrea Escelsior, Gianluca Serafini, Pasquale De Fazio, Mario Amore
Recent evidence suggests a possible relationship between the immune system and schizophrenia spectrum disorders (SSDs), as neuroinflammation appears to play a role in major psychiatric conditions. Neuroinflammation is as a broad concept representing a physiological protective response to infection or injury, but in some cases, especially if chronic, it may represent an expression of maladaptive processes
-
Insights Into the Role of Copper in Neurodegenerative Diseases and the Therapeutic Potential of Natural Compounds Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-11-15 Guangcheng Zhong, Xinyue Wang, Jiaqi Li, Zhouyuan Xie, Qiqing Wu, Jiaxin Chen, Yiyun Wang, Ziying Chen, Xinyue Cao, Tianyao Li, Jinman Liu, Qi Wang
Neurodegenerative diseases encompass a collection of neurological disorders originating from the progressive degeneration of neurons, resulting in the dysfunction of neurons. Unfortunately, effective therapeutic interventions for these diseases are presently lacking. Copper (Cu), a crucial trace element within the human body, assumes a pivotal role in various biological metabolic processes, including
-
Low-density Lipoprotein Cholesterol Reduction Therapies for Secondary Prevention in Patients with Stroke: A Network Meta-analysis Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-10-26 Xing Wang, Jun Zheng, Yuqi Chen, Chao You, Lu Ma
Background: Patients with previous strokes are at a higher risk of stroke recurrence. Current guidelines recommend a range of low-density lipoprotein cholesterol (LDL-C)-lowering treatments to reduce the risk of recurrent stroke. However, the optimal agent for decreasing LDL-C to lower the risk of recurrent stroke remains unclear. This study aimed to assess the relative effects of various LDL-C -lowering
-
The Seeking Proxies for Internal States (SPIS) Model of OCD – A Comprehensive Review of Current Findings and Implications for Future Directions Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-10-26 Amit Lazarov, Nira Liberman, Reuven Dar
: The Seeking Proxies for Internal States (SPIS) model of obsessive-compulsive disorder (OCD) explains symptoms of OCD as stemming from attenuated access to internal states, which is compensated for by using proxies, which are indices of these states that are more discernible or less ambiguous. Internal states in the SPIS model are subjective states that are not accessible to others, encompassing physiological
-
Smoking, Symptoms Improvement, and Total Antioxidant Capacity in Patients with Drug-naive First-episode Schizophrenia: A Prospective Cohort Study Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-10-19 Zhiyong Gao, Meihong Xiu, Jiahong Liu, Fengchun Wu, Xiangyang Zhang
Background: It has been hypothesized that smoking is associated with the severity of negative symptoms. Until now, no studies have investigated whether the impact of smoking on negative symptoms is dependent on antioxidants. This study was designed to evaluate the effect of smoking on therapeutic response and total antioxidants capacity (TAOC) in antipsychotic-naïve first-episode (ANFE) patients. Methods:
-
Inflammation, Autoimmunity and Neurodegenerative Diseases, Therapeutics and Beyond Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-10-17 Jenny Valentina Garmendia, Claudia Valentina De Sanctis, Viswanath Das, Narendran Annadurai, Marián Hajduch, Juan Bautista De Sanctis
Neurodegenerative disease (ND) incidence has recently increased due to improved life expectancy. Alzheimer's (AD) or Parkinson's disease (PD) are the most prevalent NDs. Both diseases are poly genetic, multifactorial and heterogenous. Preventive medicine, a healthy diet, exercise, and controlling comorbidities may delay the onset. After the diseases are diagnosed, therapy is needed to slow progression
-
Insights on Natural Products Against Amyotrophic Lateral Sclerosis (ALS) Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-10-17 Kadja Luana Chagas Monteiro, Marcone Gomes dos Santos Alcântara, Thiago Mendonça de Aquino, Edeildo Ferreira da Silva-Júnior
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that causes the death of motor neurons and consequent muscle paralysis. Despite many efforts to address it, current therapy targeting ALS remains limited, increasing the interest in complementary therapies. Over the years, several herbal preparations and medicinal plants have been studied to prevent and treat this disease
-
Three Decades of Valproate: A Current Model for Studying Autism Spectrum Disorder Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-10-17 David Zarate-Lopez, Ana Laura Torres-Chávez, Alma Yadira Gálvez-Contreras, Oscar Gonzalez-Perez
: Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder with increased prevalence and incidence in recent decades. Its etiology remains largely unclear, but it seems to involve a strong genetic component and environmental factors that, in turn, induce epigenetic changes during embryonic and postnatal brain development. In recent decades, clinical studies have shown that inutero exposure to
-
Sex Differences in Stress Response: Classical Mechanisms and Beyond Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-10-05 Georgia E. Hodes, Debra Bangasser, Ioannis Sotiropoulos, Nikolaos Kokras, Christina Dalla
Neuropsychiatric disorders, which are associated with stress hormone dysregulation, occur at different rates in men and women. Moreover, nowadays, preclinical and clinical evidence demonstrates that sex and gender can lead to differences in stress responses that predispose males and females to different expressions of similar pathologies. In this curated review, we focus on what is known about sex
-
Atypical Interpersonal Problem-Solving and Resting-state Functional Connectivity in Adolescents with Maltreatment Experience Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-10-05 Mattia I. Gerin, Essi Viding, Vanessa B. Puetz, Diana J.N. Armbruster-Genc, Georgia Rankin, Eamon J. McCrory
Background: Childhood maltreatment is associated with altered neurocognitive functioning, which is thought to reflect, in part, adaptation to early adverse environmental experiences. However, we continue to lack a precise mechanistic understanding linking atypical neurocognitive processing with social functioning and psychiatric outcomes following early adversity. Objective: The present work investigated
-
Ocrelizumab Extended Interval Dosing in Primary Progressive Multiple Sclerosis: An Italian Experience Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-10-02 Aurora Zanghì, Diana Ferraro, Graziella Callari, Paola Valentino, Franco Granella, Francesco Patti, Giacomo Lus, Simona Bonavita, Maria Claudia Moretti, Carlo Avolio, Emanuele D’Amico
Background: The intervals between two courses of anti CD20 therapies in the COVID19 pandemic era provided the opportunity to individually delay therapy, known as extended interval dosing (EID). Materials and Methods: We collect real-world data on patients with primary progressive MS (PPMS) treated with Ocrelizumab (OCR) during the COVID’19 pandemic. The observation period in which the standard interval
-
Half a Century of Research on Posttraumatic Stress Disorder: A Scientometric Analysis Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-09-28 Michel Sabé, Chaomei Chen, Wissam El-Hage, Arnaud Leroy, Guillaume Vaiva, Silvia Monari, Natacha Premand, Javier Bartolomei, Stefano Caiolo, Andreas Maercker, Robert H. Pietrzak, Marylène Cloître, Stefan Kaiser, Marco Solmi
We conducted a scientometric analysis to outline clinical research on posttraumatic stress disorder (PTSD). Our primary objective was to perform a broad-ranging scientometric analysis to evaluate key themes and trends over the past decades. Our secondary objective was to measure research network performance. We conducted a systematic search in the Web of Science Core Collection up to 15 August 2022
-
Exercise as Treatment for “Stress-Related” Mental Disorders Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-09-27 Antonia Bendau, Moritz Bruno Petzold, Jan Kaminski, Jens Plag, Andreas Ströhle
The beneficial impact of physical activity on preventing and treating mental disorders has captured growing (research) interest. This article aims to provide a concise overview of essential evidence regarding the effectiveness and underlying mechanisms of physical activity for individuals with mental disorders clustered as “stress-related” conditions. Empirical findings (e.g., longitudinalprospective
-
Abusive use of Zolpidem as a Result of COVID-19 and Perspectives of Continuity of the Problem in the Post-Pandemic Period Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-09-20 Wesley Dawison de Lima, Michael Douglas da Silva, Eurico de Souza Costa, Francisco Irochima Pinheiro, Eduardo Pereira de Azevedo, Ricardo Ney Cobucci, José Rodolfo Lopes de Paiva Cavalcanti, Fausto Pierdoná Guzen
Zolpidem is a non-benzodiazepine hypnotic drug that works as a positive modulator of Gamma-Amino Butyric Acid-A (GABA-A) receptors, with high selectivity for α1 subunits. Given this selective binding, the drug has a strong hypnotic activity. Social isolation during the SARS-CoV-2 pandemic has contributed to increased rates of anxiety, depression, and insomnia. As a result, studies have pointed to a
-
Efficacy of Low-dose Olanzapine in Combination with Sertraline on Negative Symptoms and Psychosocial Functioning in Schizophrenia: A Randomized Controlled Trial Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-09-19 Meihong Xiu, Lei Zhao, Qianqian Sun, Xiaoe Lang
Background: Evidence for the efficacy of a low dose of olanzapine (OLA) in combination with antidepressants has been limited and without positive trials in first-episode (FE) patients with schizophrenia (SCH). This study aimed to compare the efficacy in treating negative and depressive symptoms between those FE patients with SCH treated with a combination of OLA plus sertraline and those treated with
-
Chronic Lithium Treatment Alters NMDA and AMPA Receptor Synaptic Availability and Dendritic Spine Organization in the Rat Hippocampus Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-09-14 Lucia Caffino, Giorgia Targa, Anne Stephanie Mallien, Francesca Mottarlini, Beatrice Rizzi, Judith R. Homberg, Peter Gass, Fabio Fumagalli
Background: The mechanisms underlying the action of lithium (LiCl) in bipolar disorder(BD) are still far from being completely understood. Previous evidence has revealed that BD is characterized by glutamate hyperexcitability, suggesting that LiCl may act, at least partially, by toning down glutamatergic signaling abnormalities. Objective: In this study, taking advantage of western blot and confocal
-
Striatal Acetylcholine and Dopamine Interactions Produce Situationappropriate Action Selection Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-09-13 Laura A. Bradfield, Serena Becchi, Michael D. Kendig
Individuals often learn how to perform new actions for particular outcomes against a complex background of existing action-outcome associations. As such, this new knowledge can interfere or even compete with existing knowledge, such that individuals must use internal and external cues to determine which action is appropriate to the current situation. The question thus remains as to how this problem
-
Sex-Dependent Synergism of an Edible THC: CBD Formulation in Reducing Anxiety and Depressive-like Symptoms Following Chronic Stress Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-09-13 Enzo Pérez-Valenzuela, Roger Hudson, Taygun Uzuneser, Marta De Felice, Hanna Szkudlarek, Walter Rushlow, Steven R. Laviolette
: Cannabis has shown therapeutic potential in mood and anxiety-related pathologies. However, the two primary constituents of cannabis, cannabidiol (CBD) and Δ-9-tetrahydrocannabinol (THC) produce distinct effects on molecular pathways in neural circuits associated with affective disorders. Moreover, it has been proposed that the combination of THC: and CBD may have unique synergistic properties. In
-
Inhibitory Pedunculopontine Neurons Gate Dopamine-Mediated Motor Actions of Unsigned Valence Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-09-11 Sirin Zhang, Juan Mena-Segovia, Nadine K Gut
Background: The pedunculopontine nucleus (PPN) maintains a bidirectional connectivity with the basal ganglia that supports their shared roles in the selection and execution of motor actions. Previous studies identified a role for PPN neurons in goal-directed behavior, but the cellular substrates underlying this function have not been elucidated. We recently revealed the existence of a monosynaptic
-
Pathways from the Superior Colliculus to the Basal Ganglia Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-09-11 Fernando Falkenburger Melleu, Newton Sabino Canteras
The present work aims to review the structural organization of the mammalian superior colliculus (SC), the putative pathways connecting the SC and the basal ganglia, and their role in organizing complex behavioral output. First, we review how the complex intrinsic connections between the SC’s laminae projections allow for the construction of spatially aligned, visual-multisensory maps of the surrounding
-
The common denominators of Parkinson’s disease pathogenesis and methamphetamine abuse Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-09-11 Bruno Vincent, Mayuri Shukla
: The pervasiveness and mortality associated with methamphetamine abuse has doubled during the past decade suggesting a possible worldwide substance use crisis. Epitomizing the pathophysiology and toxicology of methamphetamine abuse proclaims severe signs and symptoms of neurotoxic and neurobehavioral manifestations in both humans and animals. Most importantly, chronic use of this drug enhances the
-
Involvement of the Transient Receptor Channels in Preclinical Models of Musculoskeletal Pain Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-09-08 Sabrina Qader Kudsi, Fernanda Tibolla Viero, Leonardo Gomes Pereira, Gabriela Trevisan
Background: Musculoskeletal pain is a condition that affects bones, muscles, and tendons and is present in various diseases and/or clinical conditions. This type of pain represents a growing problem with enormous socioeconomic impacts, highlighting the importance of developing treatments tailored to the patient's needs. TRP is a large family of non-selective cation channels involved in pain perception
-
Neuroprotective Effect of Tauroursodeoxycholic Acid (TUDCA) on In Vitro and In Vivo Models of Retinal Disorders: A Systematic Review Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-09-08 Jiaxian Li, Ziyang Huang, Yu Jin, Lina Liang, Yamin Li, Kai Xu, Wei Zhou, Xiaoyu Li
Background: Tauroursodeoxycholic acid (TUDCA) is a naturally produced hydrophilic bile acid that has been used for centuries in Chinese medicine. Numerous recent in vitro and in vivo studies have shown that TUDCA has neuroprotective action in various models of retinal disorders. Objective: To systematically review the scientific literature and provide a comprehensive summary on the neuroprotective
-
Central Sensitization and Pain: Pathophysiologic and Clinical Insights Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-09-06 Michele Curatolo
Central sensitization is an increased responsiveness of nociceptive neurons in the central nervous system to their normal or subthreshold afferent input. Aim: To explain how the notion of central sensitization has changed our understanding of pain conditions, discuss how this knowledge can be used to improve the management of pain, and highlight knowledge gaps that future research needs to address
-
Antioxidants, Hormetic Nutrition, and Autism Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-09-01 Sergio Modafferi, Gabriella Lupo, Mario Tomasello, Francesco Rampulla, Marialaura Ontario, Maria Scuto, Angela Trovato Salinaro, Antonio Arcidiacono, Carmelina Daniela Anfuso, Maria Legmouz, Fatima-Zahra Azzaoui, Agostino Palmeri, Sestina Spano’, Francesca Biamonte, Gaetano Cammilleri, Tilman Fritsch, Alena Sidenkova, Edward Calabrese, Uwe Wenzel, Vittorio Calabrese
Autism spectrum disorder (ASD) includes a heterogeneous group of complex neurodevelopmental disorders characterized by atypical behaviors with two core pathological manifestations: deficits in social interaction/communication and repetitive behaviors, which are associated with disturbed redox homeostasis. Modulation of cellular resilience mechanisms induced by low levels of stressors represents a novel
-
Real-World Effectiveness of Cladribine for Patients with Multiple Sclerosis: A Sicilian Multicentric Experience (Rewind Study) Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-09-01 Sebastiano Arena, Clara Grazia Chisari, Simona Toscano, Sebastiano Bucello, Luigi Maria Grimaldi, Paolo Ragonese, Sabrina Realmuto, Salvatore Cottone, Davide Maimone, Chiara Finocchiaro, Paola Reitano, Francesco Patti
Background: Cladribine tablets are a highly effective option for the treatment of relapsingremitting multiple sclerosis (RRMS). Objective: The study aims to evaluate the effectiveness of cladribine in a real-world setting. Methods: This prospective real-world study consecutively screened all RRMS patients from seven different MS centers in Sicily (Italy) who completed the 2-year treatment course of
-
Emerging Roles of Microglia in Blood-Brain Barrier Integrity in Aging and Neurodegeneration Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-09-01 Simeng Zhang, Rui Meng, Muzhou Jiang, Hong Qing, Junjun Ni
The blood-brain barrier (BBB) is a highly selective interface between the blood and the brain parenchyma. It plays an essential role in maintaining a specialized environment for central nervous system function and homeostasis. The BBB disrupts with age, which contributes to the development of many age-related disorders due to central and peripheral toxic factors or BBB dysfunction. Microglia, the resident
-
Implicit Selective Attention: The Role of the Mesencephalic-basal Ganglia System Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-08-31 Matteo Esposito, Sara Palermo, Ylenia Camassa Nahi, Marco Tamietto, Alessia Celeghin
The ability of the brain to recognize and orient attention to relevant stimuli appearing in the visual field is highlighted by a tuning process, which involves modulating the early visual system by both cortical and subcortical brain areas. Selective attention is coordinated not only by the output of stimulus-based saliency maps but is also influenced by top-down cognitive factors, such as internal
-
Use of Post-mortem Brain Tissue in Investigations of Obsessive- Compulsive Disorder: A Systematic Review Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-08-30 Christine Lochner, Petrus J.W. Naudé, Dan J. Stein
Background: Post-mortem examination of the brain is a key strategy to increase our understanding of the neurobiology of mental disorders. While extensive post-mortem research has been under taken on some mental disorders, others appear to have been relatively neglected. Objective: The objective of the study was to conduct a systematic review of post-mortem research on obsessive-compulsive disorder
-
Recombinant Antibody Fragments for Neurological Disorders: An Update Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-08-30 Goar Gevorkian, Karen Manoutcharian
: Recombinant antibody fragments are promising alternatives to full-length immunoglobulins, creating big opportunities for the pharmaceutical industry. Nowadays, antibody fragments such as antigen-binding fragments (Fab), single-chain fragment variable (scFv), single-domain antibodies (sdAbs), and bispecific antibodies (bsAbs) are being evaluated as diagnostics or therapeutics in pre-clinical models
-
Sensory Reinforced Corticostriatal Plasticity Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-08-29 Nicolas Vautrelle, Véronique Coizet, Mariana Leriche, Lionel Dahan, Jan M. Schulz, Yan-Feng Zhang, Abdelhafid Zeghbib, Paul G. Overton, Enrico Bracci, Peter Redgrave, John N.J. Reynolds
Background: Regional changes in corticostriatal transmission induced by phasic dopaminergic signals are an essential feature of the neural network responsible for instrumental reinforcement during discovery of an action. However, the timing of signals that are thought to contribute to the induction of corticostriatal plasticity is difficult to reconcile within the framework of behavioural reinforcement
-
Pathomechanistic Networks of Motor System Injury in Amyotrophic Lateral Sclerosis Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-08-25 Anant Bahadur Patel, Bedaballi Dey, Arvind Kumar
: Amyotrophic Lateral Sclerosis (ALS) is the most common, adult-onset, progressive motor neurodegenerative disorder that results in death within 3 years of the clinical diagnosis. Due to the clinicopathological heterogeneity, any reliable biomarkers for diagnosis or prognosis of ALS have not been identified till date. Moreover, the only three clinically approved treatments are not uniformly effective
-
Separation of Channels Subserving Approach and Avoidance/Escape at the Level of the Basal Ganglia and Related Brainstem Structures Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-08-24 Véronique Coizet, Racha Al Tannir, Arnaud Pautrat, Paul G. Overton
The basal ganglia have the key function of directing our behavior in the context of events from our environment and/or our internal state. This function relies on afferents targeting the main input structures of the basal ganglia, entering bids for action selection at the level of the striatum or signals for behavioral interruption at the level of the subthalamic nucleus, with behavioral reselection
-
Bibliometric Analysis of the Research Status and Global Trends in Behavioral and Psychological Symptoms of Dementia in Alzheimer’s Disease from 2002 to 2022 Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-08-24 Haipeng Cai, Ruonan Du, Kebing Yang, Wei Li, Zhiren Wang
Background: Several reviews on behavioral and psychological symptoms (BPSDs) in patients with Alzheimer’s disease (AD) have summarized the current state of this field, but global trends are unclear. Objective: This study utilized CiteSpace to provide a global overview of the current state of research on AD and its BPSDs and to predict future research trends in the field. Methods: Data were retrieved
-
Stress, Environment and Early Psychosis Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-08-18 Lida-Alkisti Xenaki, Stefanos Dimitrakopoulos, Mirjana Selakovic, Nikos Stefanis
Existing literature provides extended evidence of the close relationship between stress dysregulation, environmental insults, and psychosis onset. Early stress can sensitize genetically vulnerable individuals to future stress, modifying their risk for developing psychotic phenomena. Neurobiological substrate of the aberrant stress response to hypothalamic-pituitary-adrenal axis dysregulation, disrupted
-
Role of Cav2.3 (R-type) Calcium Channel in Pain and Analgesia: A Scoping Review Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-08-15 Juliano Ferreira, Marcella de Amorim Ferreira
Background: Voltage-gated calcium channels (VGCCs) play an important role in pain development and maintenance. As Cav2.2 and Cav3.2 channels have been identified as potential drug targets for analgesics, the participation of Cav2.3 (that gives rise to R-type calcium currents) in pain and analgesia remains incompletely understood. Objective: Identify the participation of Cav2.3 in pain and analgesia
-
Interleukin-17: A Putative Novel Pharmacological Target for Pathological Pain Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-08-15 Shao-Jie Gao, Lin Liu, Dan-Yang Li, Dai-Qiang Liu, Long-Qing Zhang, Jia-Yi Wu, Fan-He Song, Ya-Qun Zhou, Wei Mei
Pathological pain imposes a huge burden on the economy and the lives of patients. At present, drugs used for the treatment of pathological pain have only modest efficacy and are also plagued by adverse effects and risk for misuse and abuse. Therefore, understanding the mechanisms of pathological pain is essential for the development of novel analgesics. Several lines of evidence indicate that interleukin-17
-
The HPA Axis as Target for Depression Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-08-15 Andreas Menke
: Major depressive disorder (MDD) is a stress-related mental disorder with a lifetime preva- lence of 20% and, thus, is one of the most prevalent mental health disorders worldwide. Many studies with a large number of patients support the notion that abnormalities of the hypothalamus-pituitary- adrenal (HPA) axis are crucial for the development of MDD. Therefore, a number of strategies and drugs have
-
A Bibliometric and Visual Analysis of Single Nucleotide Polymorphism Studies in Depression Curr. Neuropharmacol. (IF 5.3) Pub Date : 2023-08-15 Zi Zhang, Ye Yang, Wan Kong, Shanqing Huang, Yaqian Tan, Shanshan Huang, Ming Zhang, Haoyang Lu, Yuhua Li, Xiaolin Li, Shujing Liu, Yuguan Wen, Dewei Shang
Background: Genetic polymorphism has been proven to have an important association with depression, which can influence the risk of developing depression, the efficacy of medications, and adverse effects via metabolic and neurological pathways. Nonetheless, aspects of the association between single nucleotide polymorphisms and depression have not been systematically investigated by bibliometric analysis